Comparison of the Anaesthetic Gases in Maintainance of General Anaesthesia in Paediatrics

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Desflurane and Sevoflurane are one of the modern inhalational anaesthetic agents currently in use in anaesthetic practice. The properties of desflurane that has low blood gas solubility coefficient of 0.47 compared to sevoflurane (0.68) made it more advantageous when used with supraglottic airway in maintaining general anaesthesia in paediatrics . It ensures rapid onset and offset of anaesthesia. Rapid recovery profiles especially among pediatric populations is to ensure less complications associated with prolonged recovery of anaesthesia upon emergence from anaesthesia. Nevertherless, desflurane has its drawback which is it can cause airway irritability related to its pungency. Hence, it is not used as an induction anaesthetic agent in paediatrics. This study was done to evaluate the effectiveness of desflurane in comparison to sevoflurane in maintaining spontaneous general anaesthesia in paediatrics population using Ambu AuraGain .

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Universiti Sains Malaysia
• Treatments: Desflurane; Sevoflurane

Criteria

Inclusion Criteria:

• Aged: 3 years to 12 years old.

• ASA (American Society of Anesthesiologist) I

• BMI (body mass index) less than 95 centile according to age, sex, height

• Preoperative assessment shows low risk of aspiration and no features of difficult intubation.

• No history of difficult intubation or history of admission to ICU for airway complication.

• Operation duration less or equal 2 hours using AmbuAuraGain.

Exclusion Criteria:

• Parent refusal for study participation to give informed consent.

• Patients who had an upper respiratory tract infection (URTI) within previous 2 weeks or any respiratory disease ( bronchial asthma, hyperactive airway,sleep apnea, chronic lung disease)

• Known susceptibility to malignant hyperthermia (MH)

• History of moderate to severe hepatic dysfunction following anaesthesia with desflurane not otherwise explained.